Center "Vector" registered on Wednesday the second Russian vaccine against coronavirus, said Russian President Vladimir Putin during a meeting with government members. The vaccine is registered under the name "EpiVacCorona".
“As far as I know, we have a third vaccine on the way - the Chumakov Center of the Russian Academy of Sciences,” added Vladimir Putin. His words are quoted by "Interfax".
Post-registration clinical trials of the coronavirus vaccine developed by the State Research Center "Vector" of Rospotrebnadzor will be carried out on 40 thousand volunteers, of which 150 are over 60 years old, Deputy Prime Minister Tatyana Golikova said.
"The first batches of vaccine in the amount of 60 thousand doses will be produced in the near future and Vector will begin post-registration clinical trials in various regions of Russia," Golikova said at the meeting.
She noted that the vaccine of the "Vector" center is characterized by the absence of reactogenicity and a sufficiently high level of safety. "The emergence of the second vaccine expands the possibilities of vaccination of the population, which means that it brings us closer to stabilizing and overcoming the situation with the incidence of covid," the Deputy Prime Minister added.
The vaccine "EpiVacCorona" of the state scientific center of virology and biotechnology "Vector" of Rospotrebnadzor has passed two stages of clinical trials and is awaiting registration for the transition to the post-registration stage.
The first Russian vaccine was the development of the Gamaleya Institute of the Ministry of Health of Russia, called "Sputnik V". It is a vector vaccine based on a safe adenovirus that is used as a container to deliver certain proteins of the coronavirus 'corona' into the body.
The vaccine was registered in August under the fast track procedure. She is currently undergoing a stage of post-registration research in Moscow, in which 40 thousand people will take part, a quarter of whom will receive a placebo. At the same time, it is used to vaccinate people at risk - doctors and teachers.
EpiVacCorona's post-registration studies should begin in November. The vaccine is based on "one of the promising synthetic platforms." "It is a peptide vaccine, it consists of artificially synthesized short fragments of viral peptide proteins, through which the immune system learns and subsequently recognizes and neutralizes the virus," said Tatiana Golikova. She is quoted by RBC.
The Chumakov Center has developed its own vaccine, it is a whole virion vaccine (contains a whole virus). This vaccine is also undergoing clinical trials with 300 volunteers.